免疫和肠道组织病理改善的真菌毒素结合剂
Erma Safitri1, Hery Purnobasuki2, Tita Damayanti Lestari1
1Department of Veterinary Science, Division of Veterinary Reproduction, Faculty of Veterinary Medicine, Universitas Airlangga, Surabaya, East Java, 60115, Indonesia.
F1000Research
|August 21, 2025
概括
在接种纽卡斯尔病疫苗后,菌毒素结合剂改善了 brojler 的健康和免疫力. 在被污染料养的鸟类中,剂量为1. 6g/ kg的毒素结合剂增强了抗体标位和肠道愈合.
科学领域:
- 禽类科学
- 动物营养
- 免疫学
背景情况:
- 对牛肉疫苗接种至关重要.
- 料中的菌毒素污染可能会损害疫苗接种后的免疫反应和产生.
- 黄毒素B1 (AFB1) 和黄毒素A (OTA) 是影响肉健康的常见料污染物.
研究的目的:
- 评估菌毒素结合剂在减轻AFB1和OTA对 brojler免疫和肠道健康的不良影响方面的有效性.
- 评估毒素结合剂对暴露于毒素的ND疫苗接种肉的抗体标位和组织病理变化的影响.
主要方法:
- 二十只肉被分为四组:对照组 (基础料),受菌毒素挑战组 (AFB1+OTA) 和两组接受菌毒素结合剂的治疗组,分别为1.1g/kg和1.6g/kg.
- 鸟类在第7天和第21天接种了ND疫苗.
- 在指定的几天分析了抗体标位 (血液凝结抑制试验) 和肠/结肠组织病理学.
主要成果:
- 观察到眼膜和结肠的组织病理改善,表现为粘膜破裂,出血和亡的减少.
- 在对照组和较高的菌毒素结合剂剂量组 (1. 6 g/ kg) 中,在第35天发现了抗体标位的显著增加.
- 与受毒素挑战的组相比,16g/ kg毒素结合剂组的结果明显更好.
结论:
- 一种1. 6g/ kg的真菌毒素结合剂有效地提高了AFB1和OTA的ND疫苗接种肉的抗体标位.
- 菌毒素结合剂改善了食用菌毒素污染的肉和结肠的组织病理状况.
- 在疫苗接种期间,饮食中的真菌毒素结合剂有助于维持肉的健康和免疫功能.
相关概念视频
01:18Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents
602
Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
602
01:17Drugs for Treatment of Diarrhea-Predominant IBS
1.0K
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
1.0K
01:29Drugs for Treatment of Ulcerative Colitis in IBD
705
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
705
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
692
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
692
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
820
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
820